lenalidomide has been researched along with mitoxantrone in 6 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (mitoxantrone) | Trials (mitoxantrone) | Recent Studies (post-2010) (mitoxantrone) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 4,555 | 1,042 | 1,004 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Buda, G; Galimberti, S; Orciuolo, E; Pelosini, M; Petrini, M | 1 |
| Breier, A; Coculova, M; Imrichova, D; Kavcova, H; Messingerova, L; Pavlikova, L; Seres, M; Sulova, Z | 1 |
| Amrein, PC; Attar, EC; Avigan, D; Ballen, KK; Brunner, AM; DeAngelo, DJ; Ebert, BL; Fathi, AT; Hobbs, GS; Luptakova, K; McMasters, M; Rosenblatt, J; Sperling, AS; Steensma, DP; Stone, RM; Stroopinsky, D; Wadleigh, M; Washington, A; Werner, L | 1 |
| Ballen, K; Bhatt, S; Brunner, A; Burgess, M; Carr, SA; DeAngelo, DJ; Ebert, BL; Fell, G; Garcia, JS; Keshishian, H; Letai, A; Medeiros, BC; Neuberg, D; Sperling, AS; Stone, RM; Yilma, B | 1 |
1 review(s) available for lenalidomide and mitoxantrone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for lenalidomide and mitoxantrone
| Article | Year |
|---|---|
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Analysis | 2018 |
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cytarabine; Etoposide; Female; Humans; Induction Chemotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitochondria; Mitoxantrone | 2020 |
3 other study(ies) available for lenalidomide and mitoxantrone
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Mitoxantrone; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine | 2011 |
Selection of resistant acute myeloid leukemia SKM-1 and MOLM-13 cells by vincristine-, mitoxantrone- and lenalidomide-induced upregulation of P-glycoprotein activity and downregulation of CD33 cell surface exposure.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Down-Regulation; Gene Silencing; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Mitoxantrone; Sialic Acid Binding Ig-like Lectin 3; Thalidomide; Up-Regulation; Vincristine | 2015 |